Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
The combination of **estradiol** and **sodium hyaluronate** is a therapeutic regimen investigated for the treatment of antibiotic-refractory recurrent urinary tract infections (rUTI) in postmenopausal women. This approach, often referred to as "Cocktail Therapy" in clinical study contexts, typically involves the local application of estrogen (estradiol) and the intravesical instillation of sodium hyaluronate. Estradiol acts as an estrogen receptor agonist to restore the urogenital epithelium and normalize the vaginal microbiome, which are often compromised in postmenopausal women. Sodium hyaluronate, a glycosaminoglycan (GAG), is instilled into the bladder to replenish the protective GAG layer of the urothelium, thereby reducing bacterial adherence and inflammatory irritation. This dual mechanism aims to address both the hormonal and structural vulnerabilities that contribute to chronic urinary tract infections.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on estradiol + sodium hyaluronate.